Introduction
Peyronie's disease is a sexually disabling condition of the penis whose etiology is unknown. The deformity of the penis is produced by a ®brotic scar of the tunica albuginea surrounding the corpora cavernosa which results in abnormalities in penile erection. Although this deformity of the penis was described as early as 1561 by Fallopius, it was the description of a series of patients with this deforming condition in 1743 by Peyronie which gave us the eponym. 1 Peyronie who has been called the`father of French surgery' helped establish the Royal Academy of Surgery in Paris in 1731. In an effort to legitimize the Royal Academy of Surgery, archives of surgery were begun to review common surgical problems and organize surgical techniques for various diseases. In 1743, as part of these initial volumes for the French Royal Academy of Surgery, Peyronie described a condition of ®brous cavernositis in a paper entitled`Some Obstacles Preventing Normal Ejaculation of Semen'. He suggested that the disease was caused by`irritation' and could be successfully resolved by taking the waters of Bareges in Southern France. Since that early description, many additional publications have described possible etiologies, medical and surgical treatment alternatives, but no clear solution for patients with Peyronie's disease. Early previous studies have suggested that the plaque of Peyronie's disease begins as an in¯ammatory reaction to penile trauma characterized histologically by lymphocytic and plasmacytic in®ltration of the perivascular spaces of the tissue of the tunica albuginea. Once mature, the Peyronie's plaque is rich in hyaluronic acid. The initial in¯ammatory process gradually resolves and is replaced by progressive formation of ®brous tissue associated with a perivascular ®brous collar and changes in elastic ®bers to more mature, less dispensable forms of collagen. These changes in the corpora cavernosa are similar to those found in patients with venogenic erectile incompetence.
Chiang et al 2 have described changes in collagen content and type in the entire tunica albuginea as well as the Peyronie's plaque. This change to predominately Type 3 collagen has been identi®ed in areas of the corpora cavernosa away from the plaque as well as in patients with venogenic impotence. These same authors demonstrated a decrease in glycine and alanine in Peyronie's patients plaques and distant tunica albuginea. These ®ndings imply that abnormal collagen composition and the increased presence of non-collagen protein change the tunica albuginea with decreased distensability. Other authors have demonstrated alterations in collagen of Peyronie's plaque and tunica albuginea in patients with both Peyronie's disease and priapism which are distinctly different from normal control patients.
While the etiology of Peyronie's disease continues to be an enigma, recent studies have documented the association of Peyronie's disease with other systemic local and ®brotic conditions including Duypuytren's contracture, denmatomysositis and Pagets disease of bone.
3 Further investigation of associated conditions and predisposing factors continue to clarify, albeit gradually, the underlying etiology of Peyronie's disease and associated conditions.
In this symposium, we will investigate the etiology and treatment alternatives for Peyronie's disease. Drs El-Saka and Lue review their results from research studies investigating transforming growth factor beta in Peyronie's disease. Dr Levine will review advances in medical therapy for Peyronie's disease. Surgical intervention will be discussed by Drs Pryor, Jordan and Carson. Conservative surgical procedures with plication and Nesbit procedure will be reported by Dr Pryor, plaque excision and grafting by Dr Jordan, and penile prosthesis implantation with plaque incision or modelling will be discussed by Dr Carson.
